美国 - 英文 - NLM (National Library of Medicine)

glaxosmithkline llc - epoprostenol sodium (unii: 4k04iq1of4) (epoprostenol - unii:dcr9z582x0) - epoprostenol 0.5 mg - flolan is indicated for the treatment of pulmonary arterial hypertension (pah) (who group i) to improve exercise capacity. trials establishing effectiveness included predominantly (97%) patients with new york heart association (nyha) functional class iii-iv symptoms and etiologies of idiopathic or heritable pah (49%) or pah associated with connective tissue diseases (51%). flolan is contraindicated in patients with heart failure caused by reduced left ventricular ejection fraction [see clinical studies (14.3)] . flolan is contraindicated in patients with a hypersensitivity to the drug or any of its ingredients. risk summary limited published data from case series and case reports have not established an association with flolan and major birth defects, miscarriage or adverse maternal or fetal outcomes when flolan is used during pregnancy. there are risks to the mother and fetus from untreated pulmonary arterial hypertension (see clinical considerations) . in animal reproduction studies, pregnant rats and rabbi

美国 - 英文 - NLM (National Library of Medicine)

actelion pharmaceuticals us, inc. - epoprostenol sodium (unii: 4k04iq1of4) (epoprostenol - unii:dcr9z582x0) - epoprostenol sodium 1500000 ng in 10 ml

美国 - 英文 - NLM (National Library of Medicine)

jubilant hollisterstier general partnership - epoprostenol (unii: dcr9z582x0) (epoprostenol - unii:dcr9z582x0) - epoprostenol 1500000 ng in 10 ml

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - epoprostenol sodium, quantity: 1.593 mg (equivalent: epoprostenol, qty 1.5 mg) - injection, powder for - excipient ingredients: sodium chloride; sodium hydroxide; mannitol; glycine - flolan is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with: idiopathic pulmonary arterial hypertension; familial pulmonary arterial hypertension; pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - epoprostenol sodium, quantity: 0.531 mg (equivalent: epoprostenol, qty 0.5 mg) - injection, powder for - excipient ingredients: sodium chloride; sodium hydroxide; mannitol; glycine - flolan is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with: idiopathic pulmonary arterial hypertension; familial pulmonary arterial hypertension; pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

ph10.5) for solution for infusion vials (advanz pharma - epoprostenol sodium - powder and solvent for solution for infusion - 500microgram

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

ph10.5) for solution for infusion vials (advanz pharma - epoprostenol sodium - powder and solvent for solution for infusion - 1.5mg

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

ph12) for solution for infusion vials (sun pharmaceutical industries europe b.v. - epoprostenol sodium - powder for solution for infusion - 500microgram

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

ph12) for solution for infusion vials (sun pharmaceutical industries europe b.v. - epoprostenol sodium - powder for solution for infusion - 1.5mg

美国 - 英文 - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - epoprostenol sodium (unii: 4k04iq1of4) (epoprostenol - unii:dcr9z582x0) -